{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:55:11Z","timestamp":1791262511242,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Health Technology Project, China","award":["(2025YBB015)"],"award-info":[{"award-number":["(2025YBB015)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10067-026-08028-8","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:47:07Z","timestamp":1773352027000},"page":"2855-2876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatiotemporal trends and socioeconomic drivers of hip-knee osteoarthritis burden in East Asia: a GBD-based modeling study (1990\u20132023)"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3416-363X","authenticated-orcid":false,"given":"Zhen-Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"1","key":"8028_CR1","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1186\/s12889-025-24569-0","volume":"25","author":"L Chang","year":"2025","unstructured":"Chang L, Tang H, Cai Z (2025) Longitudinal association between social economic status and new-onset arthritis among middle-aged and elderly adults: evidence from the CHARLS cohort. BMC Public Health 25(1):3259\u20133259","journal-title":"BMC Public Health"},{"key":"8028_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jot.2025.08.009","volume":"55","author":"T Jiang","year":"2025","unstructured":"Jiang T, Su S, Tian R, Jiao Y, Zheng S, Liu T, Yu Y, Hua P, Cao X, Xing Y, Ni P, Wang R, Yu F, Wang J (2025) Immunoregulatory orchestrations in osteoarthritis and mesenchymal stromal cells for therapy. J Orthop Translat 55:38\u201354","journal-title":"J Orthop Translat"},{"key":"8028_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-025-01534-8","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liu J, Wang Z et al (2025) The economic burden of inflammatory arthritis: a systematic review. Pharmacoeconomics. https:\/\/doi.org\/10.1007\/s40273-025-01534-8","journal-title":"Pharmacoeconomics"},{"key":"8028_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-025-00188-1","author":"D Lazarevi\u0107","year":"2025","unstructured":"Lazarevi\u0107 D, Stamenkovi\u0107 H, Stankovi\u0107 T et al (2025) Impact of biologic therapy, school success, parent\u2019s education and socioeconomic status on transition readiness in adolescents with juvenile idiopathic arthritis and their parents. Indian Pediatr. https:\/\/doi.org\/10.1007\/s13312-025-00188-1","journal-title":"Indian Pediatr"},{"issue":"7","key":"8028_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3855\/jidc.20882","volume":"19","author":"P Rajasekharan","year":"2025","unstructured":"Rajasekharan P, Hegde A, Mane P et al (2025) Rapid bedside testing for septic arthritis: evaluating cost-effective diagnostic tools. Journal of infection in developing countries 19(7):1108\u20131114","journal-title":"Journal of infection in developing countries"},{"key":"8028_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annepidem.2025.07.025","volume":"110","author":"M Ausserwinkler","year":"2025","unstructured":"Ausserwinkler M, Flamm M, Gensluckner S et al (2025) Exploring the link between socioeconomic factors and rheumatoid arthritis: insights from a large Austrian study. Annals of epidemiology 110:66\u201371","journal-title":"Annals of epidemiology"},{"issue":"1","key":"8028_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41927-025-00501-2","volume":"9","author":"J Ainsworth","year":"2025","unstructured":"Ainsworth J, Bolic M, Ismail I et al (2025) Sociodemographic and economic barriers to initial specialist care for patients with rheumatoid arthritis: a scoping review. BMC Rheumatol 9(1):76\u201376","journal-title":"BMC Rheumatol"},{"issue":"6S1","key":"8028_CR8","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.jval.2025.04.1936","volume":"28","author":"T Gebrye","year":"2025","unstructured":"Gebrye T, Mbada EC, Fatoye TC et al (2025) EE337 economic burden of rheumatoid arthritis in low- and middle-income countries: systematic review. Value Health 28(6S1):S123\u2013S124","journal-title":"Value Health"},{"issue":"6S1","key":"8028_CR9","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1016\/j.jval.2025.04.1879","volume":"28","author":"EM Nita","year":"2025","unstructured":"Nita EM, Silva N, Aguiar FB et al (2025) EE280 clinical and economic analysis in rheumatoid arthritis treatment: a managed care experience. Value Health 28(6S1):S114\u2013S114","journal-title":"Value Health"},{"issue":"S1","key":"8028_CR10","first-page":"1164","volume":"84","author":"R Beesley","year":"2025","unstructured":"Beesley R, Fleet KL, Baildam E et al (2025) POS1068 The association between ethnicity, socioeconomic position and outcomes following initiation of methotrexate in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 84(S1):1164\u20131165","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"S1","key":"8028_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.ard.2025.06.763","volume":"84","author":"M Thomas","year":"2025","unstructured":"Thomas M, Sayre E, Harrison M et al (2025) POS1415\u2005impact of social determinants of health on outcomes among adults with arthritis: a latent class analysis of nationally representative data from the Canadian Longitudinal Study of Aging. Ann Rheum Dis 84(S1):1433\u20131433","journal-title":"Ann Rheum Dis"},{"issue":"S1","key":"8028_CR12","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.ard.2025.06.1654","volume":"84","author":"N Yajima","year":"2025","unstructured":"Yajima N, Takahashi R, Matsui T et al (2025) ABS1132\u2005evaluating financial toxicity in rheumatoid arthritis: impact of bDMARDs and tsDMARDs on patient costs: a cross-sectional study. Ann Rheum Dis 84(S1):2062\u20132062","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8028_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/msc.70111","volume":"23","author":"F Hassan","year":"2025","unstructured":"Hassan F, Paz Z, Saab A et al (2025) Peripheral geographic district and low socioeconomic status are associated with decreased access to biologics in patients with rheumatoid arthritis. Musculoskelet Care 23(2):e70111","journal-title":"Musculoskelet Care"},{"issue":"1","key":"8028_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s41927-025-00516-9","volume":"9","author":"HB Binh","year":"2025","unstructured":"Binh HB, Phuong TTN, Hang TTV et al (2025) Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling. BMC Rheumatol 9(1):60\u201360","journal-title":"BMC Rheumatol"},{"issue":"1","key":"8028_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12913-025-12908-1","volume":"25","author":"K Takahata","year":"2025","unstructured":"Takahata K, Maeda Y, Tanaka E et al (2025) Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis using a Japanese real-world web-based survey. BMC Health Serv Res 25(1):730\u2013730","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"8028_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-025-07431-x","volume":"44","author":"YQ Xu","year":"2025","unstructured":"Xu YQ, Liu QY, Tong QW et al (2025) Comparison of the clinical efficacy and pharmacoeconomics of tofacitinib and adalimumab in Chinese patients with rheumatoid arthritis: an analysis based on propensity score matching. Clin Rheumatol 44(6):1\u201310","journal-title":"Clin Rheumatol"},{"key":"8028_CR17","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.156983.2","volume":"13","author":"N Christos","year":"2025","unstructured":"Christos N, Nikolaos K, John F et al (2025) Fostering healthcare system sustainability through efficient practices: can adopting biosimilars ease the financial burden of rheumatoid arthritis? F1000Res 13:1128","journal-title":"F1000Res"},{"key":"8028_CR18","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S498994","author":"MIA Restrepo","year":"2025","unstructured":"Restrepo MIA, Gonzalez AEG, Vargas RSG et al (2025) Comprehensive insights into the economic burden of rheumatoid arthritis in Latin America: a systematic literature review of regional perspectives. Clinicoecon Outcomes Res. https:\/\/doi.org\/10.2147\/CEOR.S498994","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"8028_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14737167.2024.2442461","volume":"25","author":"VCE Melo","year":"2024","unstructured":"Melo VCE, Lasalvia P, Espitia GML et al (2024) Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia. Expert review of pharmacoeconomics & outcomes research 25(4):527\u2013534","journal-title":"Expert review of pharmacoeconomics & outcomes research"},{"issue":"2","key":"8028_CR20","first-page":"1","volume":"9","author":"SA Qadeer","year":"2024","unstructured":"Qadeer SA, Meher A, Rachel J et al (2024) Economic evaluation of total knee replacement compared with non-surgical management for knee osteoarthritis in India. PharmacoEconomics - Open 9(2):1\u201313","journal-title":"PharmacoEconomics - Open"},{"issue":"11","key":"8028_CR21","volume":"16","author":"MJ Gaddis","year":"2024","unstructured":"Gaddis MJ, Arellano E, Bialaszewski R et al (2024) Prevalence and economic burden of osteoarthritis and rheumatoid arthritis in the medically underserved Rio Grande Valley: a retrospective longitudinal analysis. Cureus 16(11):e74521","journal-title":"Cureus"},{"issue":"11","key":"8028_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/acr2.11728","volume":"6","author":"Y Huang","year":"2024","unstructured":"Huang Y, Li J, Agarwal KS (2024) Economic and humanistic burden of rheumatoid arthritis: results from the US National Survey data 2018-2020. ACR Open Rheumatol 6(11):746\u2013754","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"8028_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14737167.2024.2390041","volume":"25","author":"B Fatemi","year":"2024","unstructured":"Fatemi B, Yaghobi N, Shobeiri N et al (2024) Cost-effectiveness analysis of Tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Expert review of pharmacoeconomics & outcomes research 25(1):29\u201338","journal-title":"Expert review of pharmacoeconomics & outcomes research"},{"issue":"3","key":"8028_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004180","volume":"10","author":"M Adas","year":"2024","unstructured":"Adas M, Dey M, Norton S et al (2024) What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis audit. RMD Open 10(3):e004180","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08028-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:49:15Z","timestamp":1775792955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8028"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08028-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable. This study is a secondary analysis of anonymized, aggregated data from the Global Burden of Disease (GBD) 2023 study, a publicly available database. The GBD study itself has obtained ethical approval and adheres to strict data governance protocols. As no individual-level data was used and all data are population-level and fully anonymized, additional ethical approval and individual consent for this analysis were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}